Obsidian Therapeutics, Inc.

OBX Nasdaq SEC CIK 2130606
Follow Obsidian Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$50.7M −77.9% vs same quarter last year
EPS, diluted −$1.23 +91.7% vs same quarter last year
Operating cash flow −$36.7M −73.3% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
Q2 25 Q3 25 Q4 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing